Today, 25 August, AstriVax, a KU Leuven spin-off company, announced that it raised €30 million seed capital to build its highly innovative vaccine platform.
We are excited to be part of the strong international investment syndicate.
“This is the second time Thuja invested in a company based on technology out of the Rega institute of the KU Leuven. Again, we were impressed by the scientific work done by the team of Professor Johan Neyts and Kai Dallmeier and are confident that their novel vaccine technology will enable the development of effective vaccines to treat and prevent infectious diseases in areas of critical unmet needs” said Harrold van Barlingen, Managing Partner of Thuja Capital Management.
For more information on the seed financing round of AstriVax, we refer to the press release.
Press release Dutch
Press release English
Press release French